10x Genomics (TXG) Non-Current Assets (2018 - 2026)

10x Genomics (TXG) has 9 years of Non-Current Assets data on file, last reported at $346.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 6.91% year-over-year to $346.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 3.14% YoY), and the FY2025 full-year result was $356.9 million, up 6.78% from the prior year.
• Non-Current Assets eased to $346.0 million in Q1 2026, from $356.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $412.1 million in Q1 2023 to a low of $305.9 million in Q1 2022.
• A 5-year average of $357.6 million and a median of $355.8 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 52.16% in 2022 and fell 13.81% in 2024, its largest moves.
• Tracing TXG's Non-Current Assets over 5 years: stood at $393.9 million in 2022, then retreated by 6.3% to $369.1 million in 2023, then dropped by 9.45% to $334.2 million in 2024, then increased by 6.78% to $356.9 million in 2025, then decreased by 3.05% to $346.0 million in 2026.
• Business Quant data shows TXG's Non-Current Assets at $346.0 million in Q1 2026, $356.9 million in Q4 2025, and $367.5 million in Q3 2025.